← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Thermo Fisher Scientific TMO $249B	2,579	-46	-2%	$169B
2	2 Danaher DHR $158B	2,226	-95	-4%	$118B
3	3 Novartis NVS $279B	1,359	+17	+1%	$15.4B
4	4 Regeneron Pharmaceuticals REGN $80.1B	1,293	-28	-2%	$59.1B
5	5 Agilent Technologies A $49.1B	1,024	-58	-5%	$29.6B
6	6 Illumina ILMN $41B	723	-131	-15%	$12.3B
7	7 Alnylam Pharmaceuticals ALNY $30B	628	+33	+6%	$34.8B
8	8 Charles River Laboratories CRL $14.4B	561	-77	-12%	$8.03B
9	9 Revvity RVTY $17B	532	+1	+0.2%	$12.1B
10	10 Sarepta Therapeutics SRPT $1.78B	431	-34	-7%	$5.56B
11	11 Bruker BRKR $8.47B	399	+32	+9%	$5.07B
12	12 CRISPR Therapeutics CRSP $4.86B	397	-9	-2%	$2.2B
13	13 Ionis Pharmaceuticals IONS $7.1B	344	-11	-3%	$5.03B
14	14 Guardant Health GH $21.9B	342	+44	+15%	$5.1B
15	15 GRAIL Inc GRAL $6.24B	314	-19	-6%	$614M
16	16 BridgeBio Pharma BBIO $12.7B	304	+41	+16%	$6.45B
17	17 Qiagen QGEN $9.41B	300	-26	-8%	$5.92B
18	18 Ultragenyx Pharmaceutical RARE $1.47B	300	-13	-4%	$3.25B
19	19 Krystal Biotech KRYS $9.79B	299	+35	+13%	$4.98B
20	20 Intellia Therapeutics NTLA $1.6B	296	0	0%	$720M
21	21 Azenta AZTA $1.63B	294	-17	-5%	$1.82B
22	22 Veracyte VCYT $3.5B	287	-31	-10%	$2.51B
23	23 Vericel Corp VCEL $2.06B	277	-2	-0.7%	$2.39B
24	24 10x Genomics TXG $9.52B	274	+1	+0.4%	$996M
25	25 Arrowhead Research ARWR $8.25B	265	-4	-1%	$1.34B